SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

Autor: Evgeny Moshkovich, Leszek Czupryniak, Birute Zilaitiene, Martin Prázný, Guntram Schernthaner, Olga Sukhareva, Heinz Drexel, Andrej Janež, Lea Duvnjak, Tsvetalina Tankova, Kristine Ducena, Katarina Lalic, Harald Sourij, Tamás Várkonyi, Emil Martinka
Jazyk: angličtina
Rok vydání: 2019
Předmět:
medicine.medical_specialty
Diabetes mellitus
type 2
drug therapy
Cardiovascular diseases
Canagliflozin
therapeutic use
Benzhydryl compounds
Glucosides
Sodium-Glucose Transporter 2 Inhibitors
Endocrinology
Diabetes and Metabolism
Empagliflozin
610 Medicine & health
030209 endocrinology & metabolism
Context (language use)
Comorbidity
Type 2 diabetes
Disease
Cardiovascular disease
Dapagliflozin
SGLT2 inhibitor
lcsh:Diseases of the endocrine glands. Clinical endocrinology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Diabetes mellitus
Correspondence
Humans
Medicine
030212 general & internal medicine
Intensive care medicine
lcsh:RC648-665
business.industry
Incidence
616.379-008.64 [udc]
General Medicine
Prognosis
medicine.disease
3. Good health
Eastern european
Diabetes Mellitus
Type 2
chemistry
Cardiovascular Diseases
business
medicine.drug
Zdroj: BMC endocrine disorders, London : BioMed Central, 2019, vol. 19, no. 1, p. 1-13
Schernthaner, Guntram; Drexel, Heinz; Moshkovich, Evgeny; Zilaitiene, Birute; Martinka, Emil; Czupryniak, Leszek; Várkonyi, Tamás; Janež, Andrej; Ducena, Kristine; Lalić, Katarina; Tankova, Tsvetalina; Prázný, Martin; Smirčić Duvnjak, Lea; Sukhareva, Olga; Sourij, Harald (2019). SGLT2 inhibitors in T2D and associated comorbidities-differentiating within the class. BMC Endocrine Disorders, 19(1), p. 64. BioMed Central 10.1186/s12902-019-0387-y
BMC Endocrine Disorders
BMC Endocrine Disorders, Vol 19, Iss 1, Pp 1-13 (2019)
ISSN: 1472-6823
DOI: 10.1186/s12902-019-0387-y
Popis: Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. Conclusion CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.
Databáze: OpenAIRE
Externí odkaz: